Since HER2 targeted therapy is employed throughout the course of the treatment of HER2-positive breast cancer, even in the context of relapsed disease, we interrogated the functional interaction between CDK4/6 inhibition and HER2 inhibitors. Here, ERBB2 is linked to breast cancer.